Search

Roundtable Discussion: Marijuana Rescheduling, Cannabidiol (CBD) Product Pathways, and More While interest in cannabis and cannabis-derived products remains high, the near- and long-term future of federal regulation remains hazy. Hear directly from FDA as they discuss regulation and enforcement in...

In a conversational 30-minute forum over Zoom, Saul Ewing attorneys hosted a discussion on emerging industry developments and common issues that cannabis businesses face today. This month's program featured content covering current regulatory landscape and how it impacts your business. Interested in...

FORT LAUDERDALE, (MARCH 7, 2024) – In joining Saul Ewing as a new partner, Zachary Kobrin brings his insight from having served as general counsel for two companies to his work as a transactional and regulatory lawyer with a focus on cannabis, antitrust and other corporate law. He works in the firm...

2023 was an active year in both the cannabis and psychedelics spaces, with significant developments across policy, research, litigation, and beyond. While states have largely led on the policy front, we expect increased federal attention in both areas this year, in addition to continuation of state...

Saul Ewing attorneys hosted a timely discussion on topics relating to Minnesota’s new adult-use cannabis law. During this one-hour program, we examined the implications of the law for all Minnesota employers, including those relating to drug testing and drug-free workplace policies. We also...

Breaking (free from) the Bank: Cannabis Litigation Finance This panel provides an overview of litigation finance, explores unique aspects of cannabis litigation that make cannabis litigation finance necessary, and provides resources for cannabis attorneys and their clients as they explore litigation...

Attorney Jonathan Havens outlines what stood out for him most after reviewing the 252-page document released by the U.S. Department of Health & Human Services.